-transparent.png){kind=logo}
There is considerable circumstantial evidence to support the concept that prostaglandins of the E series can mediate hypercalcemia in neoplastic disease. However, other metabolites of prostaglandin endoperoxides could contribute to the hypercalcemia and the site of the production of prostaglandins is not established. Further analysis of prostaglandin endoperoxide metabolism in tumor and bone tissue and in the circulation will clarify the specific mechanism. The development of quantitative analysis of prostaglandin metabolites had made it possible to identify prostaglandin-dependent hypercalcemia. Therapeutic application of the inhibitors of prostaglandin cyclo-oxygenase in the treatment of patients with prostaglandin-mediated hypercalcemia is feasible, but its general usefulness remains to be evaluated. The development of antagonists to the action of prostaglandin at the affected end organ site, presumably bone, would represent an important therapeutic advance.
H W Seyberth, and
L G Raisz, and
J A Oates
December 1963,
Indian journal of pediatrics,
H W Seyberth, and
L G Raisz, and
J A Oates
April 1977,
Cancer,
H W Seyberth, and
L G Raisz, and
J A Oates
January 2008,
Reviews in urology,
H W Seyberth, and
L G Raisz, and
J A Oates
January 1980,
La Clinica terapeutica,
H W Seyberth, and
L G Raisz, and
J A Oates
December 1990,
Endocrinology and metabolism clinics of North America,
H W Seyberth, and
L G Raisz, and
J A Oates
January 1965,
Transactions of the Pacific Coast Oto-Ophthalmological Society annual meeting,
H W Seyberth, and
L G Raisz, and
J A Oates
July 1959,
A.M.A. archives of internal medicine,
H W Seyberth, and
L G Raisz, and
J A Oates
December 1981,
Israel journal of medical sciences,
H W Seyberth, and
L G Raisz, and
J A Oates
January 1965,
Acta clinica Belgica,
H W Seyberth, and
L G Raisz, and
J A Oates
February 1973,
Deutsche medizinische Wochenschrift (1946),
